This clinical trial is focused on studying a skin condition called bullous pemphigoid, which causes large, fluid-filled blisters on areas of the skin that often itch. The study is testing a new treatment called efgartigimod PH20 SC, which is given as an injection under the skin. The purpose of the study is to see if this treatment can help people with bullous pemphigoid achieve a long-lasting improvement in their condition.
Participants in the study will receive either the new treatment or a placebo, which looks like the treatment but does not contain any active medicine. The study will last for about 36 weeks, during which time participants will be monitored to see how well the treatment works and to check for any side effects. The study will also look at how the treatment affects the need for other medications, like oral corticosteroids, which are often used to manage bullous pemphigoid.
Throughout the study, participants will have regular check-ups to assess their skin condition and overall health. The goal is to determine if efgartigimod PH20 SC can help control the symptoms of bullous pemphigoid and reduce the need for other treatments. This research could lead to new options for managing this challenging skin condition.
Bulgaria 
Croatia 
Czechia 
France 
Germany 
Greece 
Hungary 
Italy 
Latvia 
Poland 
Romania 
Slovakia 
Spain 
The Netherlands